Skip to content
PICO Portalanswers from OpenAlex

Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria

PaperCitations, authors & open-access status

Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria is a paper indexed in PICO Portal from OpenAlex.

How many citations does Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria have?

PICO Portalcitation count

Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria has 65 citations in the OpenAlex counts PICO Portal stores.

When was Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria published?

PICO Portalyear

Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria has 2018 year in the PICO Portal index.

What is the open-access status of Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria?

PICO Portaloa status

Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria has closed oa status in the PICO Portal index.

What is the DOI of Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria?

PICO Portaldoi

The DOI for Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria is on the source record.

What is the PMID of Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria?

PICO Portalpmid

The PMID for Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria is on the source record.

What is the OpenAlex record for Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria?

PICO Portalopenalex

The OpenAlex for Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial